Additive therapies for cardiovascular disease: final policy recommendations

Additive therapies for cardiovascular disease: final policy recommendations

Collection:
Health Policy and Services Research
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 17, 2019
Language(s):
English
Format:
Text
Subject(s):
Cardiovascular Diseases -- drug therapy
United States
Genre(s):
Technical Report
Abstract:
The following policy recommendations from the September 26, 2019 meeting reflect the main themes and points made during the Policy Roundtable discussion about how best to apply the evidence on rivaroxaban and icosapent ethyl to policy and practice associated with the treatment of cardiovascular disease (CVD). This conversation, which can be accessed here, [https://www.youtube.com/watch?v=1FPdZEes7Ps&feature=youtu.be], immediately followed the Midwest CEPAC voting portion of the meeting
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (7 pages))
NLM Unique ID:
9918401083106676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918401083106676